BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/4/2020 8:47:30 AM | Browse: 1077 | Download: 1983
 |
Received |
|
2020-05-08 09:19 |
|
Peer-Review Started |
|
2020-05-08 09:19 |
|
First Decision by Editorial Office Director |
|
2020-06-07 23:47 |
|
Return for Revision |
|
2020-06-07 23:47 |
|
Revised |
|
2020-06-08 13:51 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-08-05 08:17 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-08-05 23:13 |
|
Articles in Press |
|
2020-08-05 23:13 |
|
Edit the Manuscript by Language Editor |
|
2020-08-17 05:59 |
|
Typeset the Manuscript |
|
2020-08-29 15:17 |
|
Publish the Manuscript Online |
|
2020-09-04 08:47 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Retrospective Study |
| Article Title |
Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jia Zeng, Ming-Hui Xie, Jing Yang, Sheng-Wu Chao and Er-Li Xu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Er-Li Xu, BMed, Associate Chief Physician, Department of Aviation Disease, Naval Medical Center of PLA, No. 338 Huaihai West Road, Changning District, Shanghai 200052, China. yijiacheng455@163.com |
| Key Words |
COVID-19; Cytokine storm; Tocilizumab; Interleukin-6; ; |
| Core Tip |
It is effective to treat with coronavirus disease 2019 (COVID-19) patients by using tocilizumab against IL-6, but it cannot completely inhibit the inflammation and cytokine storm in all patients with COVID-19. In the clinical treatment of patients, we should pay attention to the timing of drug use and other adjuvant treatments. |
| Publish Date |
2020-09-04 08:47 |
| Citation |
Zeng J, Xie MH, Yang J, Chao SW, Xu EL. Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients. World J Clin Cases 2020; 8(17): 3763-3773 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i17/3763.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i17.3763 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
